MedTrace Logo

Famotidine Outpatient COVID-19 Treatment Study

NCT04389567 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-05-06

No results posted yet for this study

Summary

A retrospective case series of patients who self-medicated with Famotidine during coronavirus disease 2019 (COVID-19). The study will collect de-identified patient reported outcome measures of patients with confirmed COVID-19 who self-medicated with Famotidine at any dose during the period of illness. Data will be collected by questionnaire and telephone interview.

Inclusion criteria:

Age\>18; Ability to give written informed consent for study participation; Confirmed diagnosis of COVID-19; Use of Famotidine at any dose during period of COVID-19 illness

Conditions

Interventions

DRUG

Famotidine

Use of oral Famotidine.

Sponsors & Collaborators

Principal Investigators

  • David A Tuveson, MD PhD · Cold Spring Harbor Laboratory

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-12
Primary Completion
2020-05-25
Completion
2020-05-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04389567 on ClinicalTrials.gov